Growth Metrics

Day One Biopharmaceuticals (DAWN) Depreciation & Amortization (CF) (2022 - 2025)

Day One Biopharmaceuticals (DAWN) has disclosed Depreciation & Amortization (CF) for 4 consecutive years, with $91000.0 as the latest value for Q4 2025.

  • For Q4 2025, Depreciation & Amortization (CF) rose 139.47% year-over-year to $91000.0; the TTM value through Dec 2025 reached $366000.0, up 297.83%, while the annual FY2025 figure was $366000.0, 297.83% up from the prior year.
  • Depreciation & Amortization (CF) was $91000.0 for Q4 2025 at Day One Biopharmaceuticals, up from $90000.0 in the prior quarter.
  • The five-year high for Depreciation & Amortization (CF) was $94000.0 in Q1 2025, with the low at $6000.0 in Q1 2022.
  • Historically, Depreciation & Amortization (CF) has averaged $34812.5 across 4 years, with a median of $15500.0 in 2022.
  • The largest annual shift saw Depreciation & Amortization (CF) crashed 69.44% in 2023 before it surged 506.67% in 2025.
  • Over 4 years, Depreciation & Amortization (CF) stood at $15000.0 in 2022, then fell by 13.33% to $13000.0 in 2023, then soared by 192.31% to $38000.0 in 2024, then soared by 139.47% to $91000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Depreciation & Amortization (CF) were $91000.0 in Q4 2025, $90000.0 in Q3 2025, and $91000.0 in Q2 2025.